GlobeNewswire

CloudCraze and Deloitte Digital Formalize Alliance to Provide Leading B2B Commerce in the Cloud

Dela

Deloitte Digital's experience in digital transformation and CloudCraze's native Salesforce commerce platform will empower B2B customers to transform their business through SaaS

CHICAGO, May 04, 2017 (GLOBE NEWSWIRE) -- CloudCraze, the enterprise B2B commerce platform built natively on Salesforce, has collaborated with Deloitte Digital and awarded the leading creative digital consultancy Platinum Partner status, the highest level in the CloudCraze partner program. Together, they deliver full-service cloud-based B2B commerce solutions for enterprises in the manufacturing and consumer goods industry that are quick to implement, Salesforce-integrated and more profitable long term.

The alliance enhances the value that both companies bring to B2B commerce customers through the combination of Deloitte Digital's deep technological experience, industry insight and full suite of implementation services and CloudCraze's cloud-based B2B platform delivering speed to revenue, flexibility and customer focus. Deloitte Digital's vast industry experience and robust offerings have already made them instrumental for implementations with several of CloudCraze's high profile customers, including a large multi-national beverage and brewing company and one of the largest member-owned agricultural cooperatives.

"Deloitte Digital's creative, cloud-based approach to digital transformation has been a major asset for our customers over the years and our combined solutions provide unmatched value," said Ray Grady, president and chief customer officer at CloudCraze. "We look forward to leveraging Deloitte Digital's vast industry experience and are excited to have them on board as an integral CloudCraze Platinum Partner."

CloudCraze has worked closely with Deloitte Digital to build accelerated solutions. They combine a unique set of solutions and platforms, including Salesforce and CloudCraze commerce on Salesforce, to offer Deloitte customers a unified customer experience across the digital enterprise. The interactive platform was developed in response to customer need for a more robust integration of digital cloud platforms across CRM, commerce, digital marketing, and other customer engagement channels.

"Working with CloudCraze has allowed us to create even more engaging, strategic and flexible B2B commerce solutions with CloudCraze's unique speed-to-market and cloud-first, SaaS-based approach to customer engagement," said Paul do Forno, managing director, Deloitte Consulting LLP, and commerce and content practice lead at Deloitte Digital. "CloudCraze's unique offerings strengthen the digital ecosystem platform we have built and we're excited about the value the strategic alliance will bring our combined customer base."

This alliance comes at a time of growing importance for robust digital offerings in B2B. Estimates from Gartner show the digital commerce platform market will have grown at a compound annual growth rate of over 15 percent from 2015 through 2020. With a cloud-first, customer-centric approach to commerce, the CloudCraze and Digital Deloitte's joint services will enable B2B companies to stay ahead of the SaaS adoption curve, offering them a more efficient and engaging approach to commerce.

About CloudCraze
CloudCraze delivers robust B2B commerce native on Salesforce. It allows businesses to generate online revenue fast and easily scale for growth. Its Customer-First Commerce model puts the customer at the core, informing every interaction with data across commerce, sales, marketing, service and more. With the Salesforce's trusted infrastructure and core capabilities, CloudCraze provides infinite flexibility to extend functionality, add products and channels, and conduct billions of dollars in transactions anywhere. CloudCraze powers Customer-First Commerce for industry leaders such as AB InBev, Barry-Callebaut, Coca-Cola, Ecolab, GE, Kellogg's, L'Oreal, Symantec, and WABCO.

CloudCraze is funded by Insight Venture Partners and Salesforce Ventures.  

CloudCraze is recognized in The Forrester Wave(TM): B2B Commerce Suites, Q1 2017 and as a Visionary in the Gartner Magic Quadrant for Digital Commerce 2017.

About Deloitte
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including 80 percent of the Fortune 500 and more than 6,000 private and middle market companies. Our people work across more than 20 industry sectors to deliver measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to make their most challenging business decisions with confidence, and help lead the way toward a stronger economy and a healthy society.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

Media contacts
Rachel Gulden
Senior Account Executive
rachel.gulden@walkersands.com
312.267.0530




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CloudCraze via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement15.10.2018 13:25Pressmeddelande

STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health. Palette Life Sciences (former Pharmanest) has announced a licensing agreement with Nestlé Skin Health. The agreement gives Palette Life Sciences the worldwide commercialization and development rights for three products: Deflux®, Solesta® and BarrigelTM. The products are all based on the NASHATM (Non Animal Stabilized Hyaluronic Acid) technology. Palette Life Sciences will focus immediately on sales of Deflux and Solesta and will begin preparing for worldwide commercialization of Barrigel. Nestlé Skin Health will continue to manufacture the products on behalf of Palette Life Sciences. Palette Life Science will continue the development of SHACT under the name LidbreeTM. Lidbree will be submitted for European regulatory review later this year. Karolinska Development is a passive investo

Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement15.10.2018 13:25Pressmeddelande

STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health. Palette Life Sciences (former Pharmanest) has announced a licensing agreement with Nestlé Skin Health. The agreement gives Palette Life Sciences the worldwide commercialization and development rights for three products: Deflux®, Solesta® and BarrigelTM. The products are all based on the NASHATM (Non Animal Stabilized Hyaluronic Acid) technology. Palette Life Sciences will focus immediately on sales of Deflux and Solesta and will begin preparing for worldwide commercialization of Barrigel. Nestlé Skin Health will continue to manufacture the products on behalf of Palette Life Sciences. Palette Life Science will continue the development of SHACT under the name LidbreeTM. Lidbree will be submitted for European regulatory review later this year. Karolinska Development is a passive investo

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum